NeoGenomics offers a suite of LDT-validated targeted clinical assays for hematological malignancies. These assays go beyond cells identification, delivering detailed prognostic insights into malignant cell populations.
- Highly controlled and standardized staining and acquisition procedures
- Data analysis by trained and licensed clinical laboratory scientists
- Review by board-certified hematopathologists
New MRD solution
AML NanoMRD™
Transforming AML MRD: Minimal sample, maximum confidence, faster decisions.
An innovative, off-the-shelf, single-tube solution enabling precise and reliable relapse-risk assessment, deeper measurement of therapeutic response, and robust AML MRD tracking even with limited sample availability.
Earlier access to deeper clinical insights enables biopharma partners to make more informed development decisions, reduce program risk, and accelerate therapeutic development timelines.
Explore our comprehensive selection of off-the-shelf MRD assays
CTA style
Default